Micro-RNA 150-5p Predicts Overt Heart Failure in Patients with Univentricular Hearts

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Oct 11

PMID 31600281

Citations 17

Authors

Masood Abu-Halima

Eckart Meese

Mohamad Ali Saleh

Andreas Keller

Hashim Abdul-Khaliq

Tanja Raedle-Hurst

Affiliations

Soon will be listed here.

Abstract

Background: In patients with left heart failure, micro-RNAs (miRNAs) have been shown to be of diagnostic and prognostic value. The present study aims to identify those miRNAs in patients with univentricular heart (UVH) disease that may be associated with overt heart failure.

Methods: A large panel of human miRNA arrays were used to determine miRNA expression profiles in the blood of 48 UVH patients and 32 healthy controls. For further selection, the most abundantly expressed miRNA arrays were related to clinical measures of heart failure and selected miRNAs validated by polymerase chain reaction were used for the prediction of overt heart failure and all-cause mortality.

Results: According to microarray analysis, 50 miRNAs were found to be significantly abundant in UVH patients of which miR-150-5p was best related to heart failure parameters. According to ROC analysis, NT-proBNP levels (AUC 0.940, 95% CI 0.873-1.000; p = 0.001), miR-150-5p (AUC 0.905, 95% CI 0.779-1.000; p = 0.001) and a higher NYHA class ≥ III (AUC 0.893, 95% CI 0.713-1.000; p = 0.002) were the 3 most significant predictors of overt heart failure. Using a combined biomarker model, AUC increased to 0.980 indicating an additive value of miR-150-5p. Moreover, in the multivariate analysis, a higher NYHA class ≥ III (p = 0.005) and miR-150-5p (p = 0.006) turned out to be independent predictors of overt heart failure.

Conclusion: In patients with UVH, miR-150-5p is an independent predictor of overt heart failure and thus may be used in the risk assessment of these patients.

Citing Articles

Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma.

Tantawy M, Langaee T, Wang D, Rubinstein S, Cornell R, Lenihan D Int J Mol Sci. 2024; 25(14).

PMID: 39063038 PMC: 11276722. DOI: 10.3390/ijms25147795.

Non-coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease.

Caporali A, Anwar M, Devaux Y, Katare R, Martelli F, Srivastava P Nat Rev Cardiol. 2024; 21(8):556-573.

PMID: 38499868 DOI: 10.1038/s41569-024-01001-5.

Ferroptosis: A New Mechanism in Diabetic Cardiomyopathy.

Song Z, Wang J, Zhang L Int J Med Sci. 2024; 21(4):612-622.

PMID: 38464828 PMC: 10920843. DOI: 10.7150/ijms.88476.

Expression profiling analysis reveals key microRNA-mRNA interactions in patients with transposition of the great arteries and systemic left and right ventricles.

Abu-Halima M, Wagner V, Rishik S, Raedle-Hurst T, Meese E, Abdul-Khaliq H Front Cardiovasc Med. 2023; 9:1056427.

PMID: 36712263 PMC: 9878113. DOI: 10.3389/fcvm.2022.1056427.

Role of Different Types of miRNAs in Some Cardiovascular Diseases and Therapy-Based miRNA Strategies: A Mini Review.

Fayez S, Mishlish S, Saied H, Shaban S, Suleiman A, Hassan F Biomed Res Int. 2022; 2022:2738119.

PMID: 36187500 PMC: 9519277. DOI: 10.1155/2022/2738119.

References

Baek J, Bae E, Ko J, Kim G, Kwon B, Lee S . Late hepatic complications after Fontan operation; non-invasive markers of hepatic fibrosis and risk factors. Heart. 2010; 96(21):1750-5. DOI: 10.1136/hrt.2010.201772. View

Ovchinnikova E, Schmitter D, Vegter E, Ter Maaten J, Valente M, Liu L . Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. 2015; 18(4):414-23. DOI: 10.1002/ejhf.332. View

Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo M, Siniscalchi M . Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail. 2013; 15(11):1277-88. DOI: 10.1093/eurjhf/hft088. View

Van De Bruaene A, Hickey E, Kovacs A, Crean A, Wald R, Silversides C . Phenotype, management and predictors of outcome in a large cohort of adult congenital heart disease patients with heart failure. Int J Cardiol. 2017; 252:80-87. DOI: 10.1016/j.ijcard.2017.10.086. View

Abu-Halima M, Kahraman M, Henn D, Radle-Hurst T, Keller A, Abdul-Khaliq H . Deregulated microRNA and mRNA expression profiles in the peripheral blood of patients with Marfan syndrome. J Transl Med. 2018; 16(1):60. PMC: 5848586. DOI: 10.1186/s12967-018-1429-3. View

Abu-Halima M, Meese E, Keller A, Abdul-Khaliq H, Radle-Hurst T . Analysis of circulating microRNAs in patients with repaired Tetralogy of Fallot with and without heart failure. J Transl Med. 2017; 15(1):156. PMC: 5504636. DOI: 10.1186/s12967-017-1255-z. View

Devaux Y, Vausort M, McCann G, Kelly D, Collignon O, Ng L . A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS One. 2013; 8(8):e70644. PMC: 3742776. DOI: 10.1371/journal.pone.0070644. View

Ghaferi A, Hutchins G . Progression of liver pathology in patients undergoing the Fontan procedure: Chronic passive congestion, cardiac cirrhosis, hepatic adenoma, and hepatocellular carcinoma. J Thorac Cardiovasc Surg. 2005; 129(6):1348-52. DOI: 10.1016/j.jtcvs.2004.10.005. View

Khairy P, Fernandes S, Mayer Jr J, Triedman J, Walsh E, Lock J . Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2007; 117(1):85-92. DOI: 10.1161/CIRCULATIONAHA.107.738559. View

10.

Ikeda S, Kong S, Lu J, Bisping E, Zhang H, Allen P . Altered microRNA expression in human heart disease. Physiol Genomics. 2007; 31(3):367-73. DOI: 10.1152/physiolgenomics.00144.2007. View

11.

Sano T, Ogawa M, Taniguchi K, Matsuda H, Nakajima T, Arisawa J . Assessment of ventricular contractile state and function in patients with univentricular heart. Circulation. 1989; 79(6):1247-56. DOI: 10.1161/01.cir.79.6.1247. View

12.

Gewillig M, Brown S, Eyskens B, Heying R, Ganame J, Budts W . The Fontan circulation: who controls cardiac output?. Interact Cardiovasc Thorac Surg. 2009; 10(3):428-33. DOI: 10.1510/icvts.2009.218594. View

13.

Ohuchi H, Yasuda K, Miyazaki A, Ono S, Hayama Y, Negishi J . Prevalence and predictors of haemostatic complications in 412 Fontan patients: their relation to anticoagulation and haemodynamics. Eur J Cardiothorac Surg. 2014; 47(3):511-9. DOI: 10.1093/ejcts/ezu145. View

14.

Morley-Smith A, Mills A, Jacobs S, Meyns B, Rega F, Simon A . Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device. Eur J Heart Fail. 2014; 16(8):871-9. PMC: 4145708. DOI: 10.1002/ejhf.116. View

15.

Wong L, Armugam A, Sepramaniam S, Karolina D, Lim K, Lim J . Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2015; 17(4):393-404. DOI: 10.1002/ejhf.223. View

16.

Tang Y, Wang Y, Park K, Hu Q, Teoh J, Broskova Z . MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc Res. 2015; 106(3):387-97. PMC: 4447807. DOI: 10.1093/cvr/cvv121. View

17.

Tijsen A, Pinto Y, Creemers E . Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res. 2011; 93(4):573-82. DOI: 10.1093/cvr/cvr344. View

18.

Liao J, Cao B, Zhou X, Lu H . New insights into p53 functions through its target microRNAs. J Mol Cell Biol. 2014; 6(3):206-13. PMC: 4034730. DOI: 10.1093/jmcb/mju018. View

19.

Bagnall R, Tsoutsman T, Shephard R, Ritchie W, Semsarian C . Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS One. 2012; 7(9):e44744. PMC: 3443088. DOI: 10.1371/journal.pone.0044744. View

20.

Ramachandran S, Lowenthal A, Ritner C, Lowenthal S, Bernstein H . Plasma microvesicle analysis identifies microRNA 129-5p as a biomarker of heart failure in univentricular heart disease. PLoS One. 2017; 12(8):e0183624. PMC: 5578659. DOI: 10.1371/journal.pone.0183624. View